IMRIS
RELATED CONTENT
Imris announced U.S. Food and Drug Administration (FDA) clearance to market Visius iCT, the first and only ceiling-mounted intraoperative computed tomography (iCT) on the market.
October 08, 2013 
IMRIS Inc. and Varian Medical Systems announced that data presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting demonstrates the potential to direct state-of-the-art radiation treatments using diagnostic-quality magnetic resonance (MR) images at each treatment session.
September 30, 2013
IMRIS Inc. has obtained regulatory CE mark for Visius iCT, the first and only ceiling-mounted intraoperative computed tomography (CT), allowing for sales and marketing in the European Union.
August 13, 2013
IMRIS Inc. reported that Le Bonheur Children's Hospital in Memphis, Tenn., is crediting intraoperative MRI (iMRI) within the VISIUS Surgical Theatre with reducing returns to the operating room for residual tumor removal by 84 percent over 2 years.
July 01, 2013
May 1, 2009 - IMRIS Inc. received CE Mark approval for its integrated MR imaging and X-Ray angiography suite that enables physicians to diagnose, intervene, resolve and confirm the effectiveness of treatment with one integrated system.
May 01, 2009
December 18, 2008 – The FDA has cleared the 3.0 Tesla IMRISneuro manufactured by IMRIS Inc. for sale in the U.S.
IMRISneuro is available with either a 1.5 Tesla or a 3T magnet. Both systems provide IMRIS' patented technology and utilize 70 cm wide bore advanced magnetic resonance imaging systems from Siemens.
December 18, 2008